Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
An update from AnaptysBio ( (ANAB) ) is now available.
On January 31, 2025, AnaptysBio entered an exclusive global license agreement with Vanda Pharmaceuticals for the development and commercialization of imsidolimab, an IL-36R antagonist for treating Generalized Pustular Psoriasis. Anaptys will receive $10 million upfront and $5 million for existing drug supply, with potential additional payments based on regulatory and sales milestones, alongside a 10% royalty on net sales. This agreement positions Vanda to leverage its expertise in rare diseases and inflammatory conditions for further label expansions, while Anaptys benefits from potential financial gains and strategic partnership for imsidolimab, which has completed successful Phase 3 trials.
More about AnaptysBio
AnaptysBio, Inc. is a clinical-stage biotechnology company that focuses on developing innovative immunology therapeutics for autoimmune and inflammatory diseases. Their lead program, rosnilimab, targets PD-1+ T cells and is in trials for rheumatoid arthritis and ulcerative colitis. Anaptys has also partnered with GSK for immuno-oncology therapies, including anti-PD-1 and anti-TIM-3 antagonists.
YTD Price Performance: 34.21%
Average Trading Volume: 656,453
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $545.6M
See more insights into ANAB stock on TipRanks’ Stock Analysis page.
